Torrent Pharmaceuticals

TORNTPHARM closed at ₹4,750.0 on 2026-11-06, holding near the upper end of its 20-day range (+87.8%) but below key daily moving averages and the Supertrend. This creates a mixed technical picture: the monthly trend remains strongly bullish (ADX 59.54) with price above all major indicators, while the weekly structure is also bullish. However, the daily chart shows a bearish Supertrend direction and price below the 50-period SMA, suggesting short-term distribution or consolidation despite positive returns over the last 10 days (+5.0%).

Momentum is present but contested. Anomalies on 2026-10-23 and 2026-10-26 showed high participation with wide intraday ranges or lack of clear direction, indicating active trading without decisive follow-through. The stock is currently positioned between immediate support at ₹4,749.23 (0.02% below) and resistance at ₹4,788.47 (0.81% above). A break above ₹4,788.47 could signal a resumption of the daily uptrend toward ₹4,823.53. Conversely, a close below ₹4,749.23 would expose the next support level at ₹4,714.17 (-0.75%), potentially invalidating the short-term bullish bias.

Risk metrics show an annualized volatility of +21.9% and a current drawdown of -7.3%. While the long-term return since start is +38.9%, the recent 1-month return is slightly negative (-0.5%), highlighting near-term indecision.

In the seven-day window ending November 5, 2026, Torrent Pharmaceuticals received renewed attention from domestic brokerages. On November 3, SMIFS included the company among its top stock picks for November, citing a broader resurgence in buying interest for Indian equities driven by supportive domestic and global cues, including eased crude oil prices and strong economic growth. The firm provided detailed technical analysis with specific buy ratings, target prices, and stop-loss levels for Torrent Pharma alongside other selected counters. Subsequently, on November 5, Geojit Financial Services issued a 'Buy' recommendation for the pharmaceutical company, setting a specific target price of ₹5,581. These developments reflect external analyst optimism regarding the stock's valuation and near-term potential, though they represent third-party opinions rather than verified corporate operational changes.

Torrent Pharmaceuticals reported consolidated revenue of ₹4,979 crores for Q2 FY27, marking a 51% year-on-year increase from ₹3,302 crores, driven by the amalgamation of J.B. Chemicals & Pharmaceuticals Limited (JB Pharma). The merger, effective July 8, 2026, with an appointed date of January 21, 2026, resulted in the allotment of 4,19,22,416 equity shares. Consolidated profit after tax stood at ₹534 crores for the quarter and ₹1,100 crores for H1 FY27.

In regulatory developments, the company received orders on November 4, 2026, imposing a GST penalty of ₹3,12,32,860 related to JB Pharma’s operations for FY 2020-21 to FY 2023-24. Torrent Pharmaceuticals stated it will file an appeal and does not reasonably expect a material financial impact. Additionally, the Registrar to an Issue, KFin Technologies, is shifting its corporate office address effective December 1, 2026.

Torrent Pharmaceuticals is executing a significant expansion phase, marked by a surge in sales to ₹17,400 crore (TTM) and a 51% YoY growth in the September 2026 quarter. However, earnings quality faces pressure as net profit growth stagnates (0% TTM) despite rising revenues, driven by a sharp increase in finance costs to ₹886 crore (TTM) and higher depreciation of ₹609 crore in Q2 FY2026-27. The balance sheet has expanded materially, with total assets jumping from ₹15,515 crore to ₹44,615 crore year-over-year, supported by increased borrowings (₹14,107 crore as of Sep 2026) and equity infusion. While operating cash flow remains robust at ₹3,023 crore for Mar 2026, the cash conversion cycle has lengthened to 163 days, and ROCE declined to 15% in Mar 2026 from 27% the prior year. Promoter holding diluted to 60.78%, while FIIs and DIIs increased their stakes, reflecting institutional confidence in the growth trajectory despite margin compression.

Torrent Pharmaceuticals faces near-term technical headwinds despite a strong yearly performance. On the daily chart, the stock is in a bearish trend with the Supertrend indicating downward pressure and both the 20-day and 50-day simple moving averages showing negative slopes (-10.06 and -25.79 respectively). The price has pulled back from recent highs, resulting in a current drawdown of -7.3% against a maximum historical drawdown of -14.9%. While the monthly trend remains bullish (Supertrend: bullish) and the stock is up +33.7% over the past year, the short-term momentum is weakening, evidenced by a -4.2% return over the last three months and a slight decline of -0.5% over the past month. Immediate support is thin, with the nearest pivot level at ₹4,714.17 just 0.75% below the closing price of ₹4,750.00. Investors should monitor whether the price holds above this pivot; a break below could expose further downside toward ₹4,674.93.